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Abstract
Objective: To determine the respective trends in
mortality of Zambian mother-infant pairs based on
maternal infection with HIV-1 and human herpesvirus
type 8 (HHV-8).
Methods: A prospective cohort study was done on
Zambian mother-infant pairs, stratified by maternal
serologic status and followed from 6 weeks postdelivery for 48 months. Statistical analysis of the differences
in the calculated mortality rates among the four groups
was done using Stata 7.0. Kaplan-Meier analysis and
Cox proportional hazard models were used to measure
subject survival time.
Results: Between September 1998 and March 2002, a
total of 1,425 mother-infant pairs were enrolled. The
crude mortality rate among children born to dually
infected mothers was - 9 times higher (245.90 deaths
per 1,000 live births) when compared with the death
ratio of children born to seronegative mothers (24.63
deaths per 1,000 live births). The incidence rate for

death was 0.3411,000 in infants of co-infected mothers
in comparison with 0.32/1,000 among HIV-1-infected
mothers, 0.0336/1,000 among uninfected mothers,
and 0.0403/1,000 among HHV-8-infected mothers
(X2 = 154.56; P < 0.01). Infants of co-infected mothers
had a comparable risk of death in comparison with
infants infected with HIV-1 alone {hazard ratio, 9.91
[95% confidence interval (95% Cl), 5.08-19.37] for
co-infected versus 9.26 [95% CI, 4.75-18.07] for HIVI-infected alone}. Infants of mothers infected only
with HHV-8 also had comparable survival in comparison with uninfected infants (hazard ratio, 1.21; 95%
CI, 0.56-2.61).
Conclusion: Infants born to mothers dually infected
with both HIV-1 and HHV-8 have comparable survival
with infants exposed to HIV-1 alone. Infants born to
mothers infected only with HHV-8 have comparable
survival with uninfected infants. (Cancer Epidemiol
Biomarkers Prev 2008;17(9):2238-43)

Introduction
AIDS- and HIV-1-associated mortality among both
adults and children declined significantly in the developed world following the introduction of highly active
antiretroviral therapy (1, 4). This has not been the case,
however, in those areas of the developing world where
highly active antiretroviral therapy is presently not
available. Whereas the magnitude of the AIDS epidemic
in sub-Saharan Africa has been amply described and
there are now data documenting an associated decrease
in life expectancy in this region (5), there is a paucity of
specific data about AIDS-related mortality (6) especially
among HIV-1-infected mother and child pairs. What
little data there is has been obtained primarily from
retrospective studies (6-8), which, not surprisingly, have
documented an increase in mortality among children
born to HIV-1-infected mothers. Similarly, there is as yet
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little prospective data (9) about the effect of the AIDS
pandemic on mortality in this same patient population.
Whereas the majority of these deaths are infection related
(6), there is no information on the role that other viruses
may have had in contributing to mortality in these
groups.
Zambia, located in south-central Africa, has been
severely affected by the AIDS pandemic (10). Approximately 30% of the obstetric patients at the University
Teaching Hospital in Lusaka are HIV-1 infected, and
prior reports have noted that 20% to 39% of the infants
born to these women are infected perinatally (11, 12).
Zambia has also experienced an AIDS-related epidemic
of Kaposi's sarcoma among both adults and children.
The seroprevalence of human herpesvirus type 8 (HHV8) or the Kaposi's sarcoma-associated herpesvirus, the
necessary casual agent of Kaposi's sarcoma (13-17), in
this same obstetric population in Lusaka approaches 40%
(18). HHV-8 studies with African children have found
seroprevalence ranging from 13% to 58%, depending on
the region surveyed (19-21). HHV-8 has also been
associated with primary effusion lymphoma and multicentric Castlemen's disease (22), but the natural history
of HHV-8 infection and how it might contribute to the
pathogenesis of HIV-1 infection in co-infected patients
are not known. It is also not known how or to what
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extent HHV-8 alone contributes to mortality among
African adults and children.
As part of a continuing prospective cohort study
investigating the epidemiology and natural history of
HHV-8 and HIV-1 infection among Zambian mothers
and their infants in Lusaka, Zambia, in this article, we
describe the mortality patterns in this same population.
To our knowledge, this is the first such large-scale,
prospective study of its kind. The availability of such
data will be crucial to present efforts to prioritize heath
care efforts in Zambia and other resource-limited
countries.

Materials and Methods
Study Design. A prospective cohort study investigating the epidemiology of HIV-1 and HHV-8 infection
among Zambian mothers and their infants was initiated
in September of 1998 at the University Teaching Hospital,
University of Zambia School of Medicine, Lusaka,
Zambia. The study protocol was reviewed and approved
by the Institutional Review Boards at the University
Teaching Hospital, the University of Miami School of
Medicine, and the University of Nebraska. Written
informed consent was obtained from all mothers who
were interested in participating before entry into the
study. After the consent process, blood was drawn from
the mothers for HIV-1 and HHV-8 testing. The mothers
were classified into four subgroups based on their
HHV-8 and HIV-1 serologic status: group I, HHV-8
and HIV-1 positive; group 2, HHV-8 positive only;
group 3, HIV-1 positive only; and group 4, seronegative
for both agents (used as a control for this study). Their
state of physical health was assessed at each of the
follow-up visits. The following information was recorded
at each follow-up visit: interval medical history, vital
signs and symptoms, complete physical examination,
and use of new medication with emphasis on whether
these were antibiotics or antimalarial drugs. When
patients did not return for follow-up visits, our research
staff made home visits to ensure follow-up or inquire
about possible illness or death. Death reports were
usually taken from family or friends, and in some cases,
hospital records were used if deaths occurred at the
University Teaching Hospital in Lusaka.
Patient Population. Pregnant Zambian women in the
earliest stages of labor were approached for recruitment
for the study at the time of presentation to the labor ward

at the University Teaching Hospital. Women who were in
active labor or who had >5-cm cervical dilation at the time
of presentation to the labor ward or who did not live in
Lusaka or had visible signs and/ or symptoms of AIDS,
tuberculosis, or cancer were excluded from the screening
process. In cases of multiple gestation, only the firstborn
infant was enrolled into the study. Mother-infant pairs
who returned for the first follow-up visit became part of
the active HIV-1/HHV-8 cohort, which was followed up
for this study and described in detail below.
Sample Collection and HIV-l Testing. Blood samples
from the mothers drawn before delivery were used to
determine their serologic status. Blood specimens were
collected by venipuncture in acid citrate dextrose tubes
and processed within 6 h of being drawn. Plasma was
screened for HIV-1 antibodies using two rapid assays:
Capillus (Cambridge Biotech) and Determine (Abbott
Laboratories). Both assays were done according to the
manufacturers' instructions. An immunofluorescence
assay was then used to confirm the status of any sera
that were positive by one or both of the rapid tests.
The HIV-1 immunofluorescence assay was done using a
chronically HIV-1-infected T-cell line, HUT-78/ARV
(kindly provided by Dr. Cecilia Cheng-Mayer, Aaron
Diamond AIDS Research Center, New York, NY).
Uninfected HUT-78 cells were used for background
control. Patients were considered HIV-1 infected only if
they tested positive by one or both of the rapid assays and
the confirmatory immunofluorescence assay. Any indeterminate results were resolved by subsequent testing of
specimen collected at a subsequent follow-up visit.
Immunofluorescence Assay for HHV-8. Maternal
plasma was tested for HHV-8 antibodies by indirect
immunofluorescence assay. BC-3 cells, a HHV-8-positive
and EBV-negative B-cell lymphoma cell line, were used
for the immunofluorescence assay. The immunofluorescence assay was done using the procedure described
by Lennette et al. (23) with minor modifications.
Briefly, 5 x 105 cells/mL were stimulated with 12-0tetradecanoylphorbol-13-acetate (20 ng/mL; Sigma) for
72 h in culture medium (90% RMPI 1640, 10% FCS,
100 units/mL penicillin G, and 100 ug/rnl. streptomycin).
Two lab workers tested all samples at 1:40 dilution.
To exclude false-positive results due to background
staining, all positive sera were retested with BJAB cells
(a Kaposi's sarcoma-associated herpesvirus negative B
lymphoma cell line). Only sera found to be negative with
uninfected cells were considered positive.

Table 1. Socicodemographic and clinical differences between participants and nonparticipants and their infants in
the final cohort
Variable

Participants, mean (SD) or % (n = 1,424)

Maternal age (y)
Marital status (% married)
Infant sex (% female)
Birth-weight (g)
Apgar 5 min
Maternal HIV-l+/HHV-8+ (%)
Maternal HIV-l+ (%)
Maternal HHV-8+ (%)
Maternal HIV-l-/HHV-8- (%)

24.96 (6.09)
90.10
48.12
2,972.52 (503.55)
8.93 (0.44)
17.06
35.39
18.89
28.65

Nonparticipants, mean (SD) or % (n
23.67 (5.87)
88.72
47.54
2,916.48 (538.18)
8.75 (1.10)
13.80
22.72
11.88
51.59

2

*x and t tests were used to test for significance.
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= 1,737)

p*
<0.01
0.21
0.75
<0.01
<0.01

<0.01

2239

2240

No Increased Risk from Co-infection with HIV-1 and HHV-8

Table 2. Number of deaths among mothers and
infants according to mother's serologic status
Serologic status of mother
HIV-1 and HHV-8 infected
HHV-8 infected
HIV-1 infected
Noninfected
Total

No. infant
deaths'

No. deaths

Total

in mother

60
19
62
10
151

18
3
18
0
37

76
22
80
10
188

·x2 = 146.53, P
t

< 0.01 (for group serostatus for infants).
X2 = 51.42, P < 0.01 (for group serostatus for mothers).

Statistical Analysis. The data analyzed included
information collected during the 48 months of followup. Statistical analysis was done using Stata 8.0. Both
descriptive and inferential analyses were used (24, 25).
Between-group comparisons were carried out by calculating standardized mortality ratios using the mortality
rate of infants of mothers not infected with either virus as
the standard. Group-specific standardized mortality
ratios were calculated as follows: observed deaths/
expected deaths. Differences in mortality among the four
groups were assessed by X2 analysis and determination
of relative risk of death. Respective differences in
survival were assessed by Kaplan-Meier survival analysis and Cox proportional hazard models. A log-rank test
was used to compare the equality of survival time among
infants born to dually infected mothers, infants born to
uninfected mothers, and infants born to mothers infected
with HIV-1 and HHV-8 alone.
Results
Patient Enrollment. Mother-infant pairs were
recruited at the University Teaching Hospital over a
42-month period from September 1998 until March 2002.
Three thousand one hundred sixty-one were initially
recruited after providing informed consent. Of these,
1,425 (45.1%) returned for the first follow-up visit as per
the protocol schedule and formed the basis of the cohort,
which was subsequently followed to obtain data for this
analysis. We have HIV and HHV-8 serology on 1,424 of
the 1,425 recruited for the cohort. We had previously
reported that of the 3,150 screened mothers, 438 were
dually infected with both HIV-1 and HHV-8, 818 were
positive for HHV-8 alone, and 519 were positive for
HIV-1 alone (18). One thousand three hundred seventyfive (1,375) tested negative for both HIV-1 and HHV-8.
The seroprevalences of HIV-1 and HHV-8 in the group as
a whole were 30.38% and 39.87%, respectively. Forty-five
percent (1,428) of these mothers returned for the first

research visit and constituted the cohort followed based
on the mothers' willingness to continue in the study.
Each of the mother-infant pairs was assigned to one of
four groups based on the mother's serologic status:
group 1 (mother HIV-1+, HHV-8+), 244 mother-infant
pairs; group 2 (mother HIV-1-, HHV-8+), 503 motherinfant pairs; group 3 (mother HIV-1+, HHV-8-), 271
mother-infant pairs; and group 4 (mother HIV-1-, HHV8-), 406 mother-infant pairs. There were some small
differences in the sociodemographic maternal and infant
delivery variables between the 1,737 mother-infant pairs
who did not return for the first follow-up visit and the
1,424 mother-infant pairs that compose the final cohort.
Participants were slightly older than nonparticipants,
24.96 versus 23.67 years (P < 0.01; Table 1). Study
nonparticipant infants had slightly lower birth-weight
(P < 0.01) and Apgar scores at 5 minutes (P < 0.01)
than the infants of women who decided to participate
in the study. Participants were also more likely to be
co-infected with HIV-1/HHV-8 and infected solely with
HIV-1 and HHV-8 in comparison with nonparticipants
(P < 0.01). Data for mortality were analyzed from the first
date of recruitment, September 14, 1998, through 48
months of follow-up.
Infant Mortality and Follow-up of Cohort. There
were a total of 190 deaths, 151 among the infants and 37
among the mothers during the 48 months of the study
period (Table 2). The majority of the infant deaths (122 of
151, 80.79%) occurred among those who were born to
HIV-1-infected mothers (60 in group 1 and 62 in group
3, with group-specific death rates of 245.90 and 228.78
per 1,000 live births, respectively; Table 3). Of the infants
who died (n = 151), the mean age of death was 15.07 ±
11.55 months and the median age of death was 12.00
months.
The crude child mortality rate for the entire cohort was
106.04 deaths per 1,000 live births. The group-specific
child mortality rates ranged between 24.63 deaths per
1,000 births for group 4 and 245.90 deaths per 1,000births
for group 1. Children of uninfected mothers (group 4)
had the fewest deaths and were used to calculate the
standardized child mortality ratios. Children of HHV-8
and HIV-1 co-infected mothers were -10 times more
likely to die when compared with the children born to
the uninfected mothers [hazard ratio (HR), 9.91; 95%
confidence interval (95% Cl), 5.08-19.37; Table 5],
whereas those whose mothers were infected with
HHV-8 only had no greater mortality risk (HR, 1.21;
95% Cl, 0.56-2.61; Table 5). Adjusting for maternal age,
5-minute Apgar score, maternal death, and infant birthweight, the HRs did not change significantly, indicating
that potential confounding factors did not change these
associations [HR(adj), 10.58 (95% cr. 5.23-21.41), for risk

Table 3. Standardized infant mortality ratios
Serologic status of mother

No. deaths

Group-specific deaths per 1,000

Standardized mortality ratio

HIV-1+/HHV-8+ (n = 244)
HHV-8+ (n = 503)
HIV-1+ (n = 271)
Noninfected (n = 406)'
Total (n = 1,424)

60
19
62
10
151

245.90
37.77
228.78
24.63
106.04

9.98
1.53
9.29
1.00
4.31

'The noninfected group serves as the reference group.
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Table 4. Differences between participants and those lost to follow-up at 48 mo
Variable
Maternal age (y)
Marital status (% married)
Infant sex (% female)
Birth-weight (g)
Apgar 5 min
Maternal HlV-1+/HHV8+ (%)
Maternal HIV-1+ (%)
Maternal HHV-8+ (%)
Maternal HIV-1-/HHV-8- (%)

Participants, mean (SD) or % (n

= 878)

Nonparticipants, mean (SD) or % (n = 368)

25.38 (6.32)
90.76
49.46
3,000.13 (489.25)
8.93 (0.45)
13.59
45.38
16.06
34.17

24.67 (6.10)
89.86
47.15
2,992.65 (521.03)
8.92 (0.46)
13.90
35.88
14.40
26.63

p*
0.06
0.63
0.46
0.61
0.69

<0.01

NOTE: Data exclude those mothers who died or had infants who died before 48 rna of age.
*X2 and t tests were used to test for significance.

of death for children of co-infected mothers in comparison with children of uninfected mothers, and 10.01
(95% Cl, 4.96-20.20), for infants of HIV-l+ mothers;
Table 6]. The adjusted HR for infants from mothers
infected with HHV-8 alone in comparison with uninfected infants was 1.38 (95% Cl, 0.63-3.06). Infants from
dually infected mothers (group 1) were 8.18 times more
likely to die when compared with infants whose mothers
were infected with HHV-8 alone [HR, 8.18 (95% ci, 4.8813.71); HR(adj), 7.65 (95% cr. 4.53-12.91)]. There was no
increased risk of death among the coaffected infants
(group 1) when compared with those infants perinatally
exposed to HIV-l alone [group 1 versus group 3; HR,
1.07 (95% cr. 0.75-1.53); HR(adj), 1.06 (0.74-1.51)].
We did not find any differences between those lost to
follow-up at 48 months and those still in the cohort with
regard to maternal age, infant birth-weight, infant Apgar
score at 5 minutes, or infant sex. We did see important
differences in HIV-l and HHV-8 seropositivity between
those lost to follow-up and those still in the cohort at
48 months. Participants were more likely to be infected
with HIV-l alone in comparison with nonparticipants
(45.38% versus 35.88%), but there were no significant
differences in the prevalence of co-infection. Participants
were followed for a mean of 26.60 ± 18.13 months (range,
0-48 months; Table 4).
Maternal Mortality. A total of 37 death events occurred
among the mothers: 16 among co-infected mothers,
3 among HHV-8 infected mothers, and 18 among those
infected only with HIV-1. Mothers who were co-infected
with HHV-8 and HIV-1 did not have a lower survival than
mothers infected with HIV-l alone (HR, 0.95; 95% Cl,
0.49-1.87). As the number of events was small, we were
unable to assess the difference in survival between
uninfected mothers and those infected with HHV-8.
Infant Mortality and Survival Data. Survival data
were obtained from the 1,424 mother and child pairs
followed up during the 48-month study period. The
mean time of death was 14.40 (±11.09) months for group
1, 15.07 (±11.70) months for group 2, 16.47 (±12.46)
months for group 3, and 10.36 (±7.16) months for group
4. These trends were confirmed by Kaplan-Meier survivorship analysis. When the four separate groups of
infants were plotted separately, children that were born
to the HIV-l and HHV-8 co-infected mothers showed the
poorest survival with an incidence rate of death being
0.34/1,000 and those infected with HIV-l having an
incidence rate of death of 0.32/1,000. Uninfected children
had an incidence rate of death of 0.0336/1,000, as did

those infected only with HHV-8. The log-rank test for
equality of survival functions indicates statistically
significant differences between groups (X 2 = 154.56,
P < 0.01; Fig. 1).

Discussion
Kaposi's sarcoma, previously the most common neoplasm
associated with AIDS, is responsible for extensive morbidity and increased mortality in this patient population
(26). Although endemic in sub-Saharan Africa, its incidence and diversity in terms of the segments of the
population affected have both markedly increased since
the advent of the global HIV-l pandemic (17, 22, 26, 27).
This is especially true in Zambia where Kaposi's sarcoma
rates have increased among men, women, and children
(13-16). With the increasing prevalence of HIV, Zambia
has reported a Ifl-fold increase in the incidence of
pediatric Kaposi's sarcoma. Before 1986, Kaposi's sarcoma
accounted for 6.02% of all childhood cancers; between
1987 and 1992, it accounted for 19.34% of all tumors in
children in Zambia, making it the second most common
childhood tumor. Fifty-nine percent of reported cases
occurred in children under 4 years of age, the peak
incidence being between 1 and 2 years of age (15, 17).
The necessary causal agent of Kaposi's sarcoma, HHV8, is also endemic in sub-Saharan Africa (22,28,29). Most
infections occur in early childhood, with a linear increase
in prevalence during adulthood. Whereas it seems to be
transmissible sexually between homosexual and heterosexual partners (30-36), its exact modes of horizontal and
vertical transmissions have not been delineated (37-40).
Our study was designed to describe the epidemiology
and natural history of HHV-8 infection among Zambian
mothers and their infants. We also were interested
in studying the potential effect of HHV-8 and HIV-l
co-infection in these same mother-infant pairs. The latter
objective formed the basis for this mortality analysis.
Retrospective studies from Zambia, Uganda, and Cote
Table 5. Infant survival: Cox proportional hazards
model
Serostatus
Uninfected
HlV -1+/HHV-8+
HIV-1-/HHV-8+
HlV-1+/HHV-8-
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HR (95% en
1.00
9.91 (5.08-19.37)
1.21 (0.56-2.61)
9.26 (4.75-18.07)

2241

2242

No Increased Risk from Co-infection with HIV-1 and HHV-8

Table 6. Infant survival: Cox proportional hazards
model
Adjusted* HR (95% en

Serostatus
Uninfected
HlV-1+/HHV-8+
HIV-1-/HHV-8+
HIV-1+/HHV-8-

1.00
10.58 (5.23-21.41)
1.38 (0.63-3.06)
10.01 (4.96-20.20)

*Adjusted for maternal age, 5 min Apgar, infant birth-weight, and
maternal death.

d'Ivoire have found a mortality rate under 5 years of age
of 151 to 163 deaths per 1,000 births among HIV-exposed
children (6-8),clearly exceeding the targeted goal of 98 to
132 deaths per 1,000 births set by the United Nations
during 1991 (10). A retrospective study of 193 vertically
infected children from a socioeconomically disadvantaged neighborhood in Cape Town, South Africa found
that 34% of these children died before their 5th birthday
(7). Prospective data from a perinatally exposed cohort of
infants in Durban, South Africa documented a similar
mortality rate, with 35.4% of the infants having died after
48 months of follow-up (6). Whereas the Durban study
was free of the bias of. earlier, retrospective studies of
only symptomatic children, the number of infants
followed in this study was relatively small (181, of which
48 were infected, 93 uninfected, and 40 remained
indeterminate).
The exact causes of death among those 25 infants who
died were not specified, although diarrhea, severe
thrush, marasmus, and pneumonia were among the
most common causes of morbidity among those 17
children dying of AIDS in the Durban study. The mean
age at death in this latter group was 10.1 months (range,
1-48 months), with 83% of these deaths occurring before
the age of 10 months. Additional prospective data from
Rwanda (9) documented an estimated risk of death
among HIV-1-infected children of 45% at 2 years and
62% at 5 years. The latter was 21 times the rate observed
among uninfected children.

During the 48 months of follow-up in this study, we
documented an overall infant mortality rate of 106.04
deaths per 1,000 live births. This figure was higher than
the 2001 estimates of infant deaths in Zambia of 90.89
deaths per 1,000 live births (38). Not surprisingly, the
majority of deaths occurred among infants perinatally
exposed to HIV-1. A similar mortality rate, however,
occurred among infants born to mothers infected with
both viral agents (group 1). Additionally, infants of
mothers infected with HHV-8 had a similar rate of death
in comparison with uninfected infants (group 4).
Our survival analysis identified a clear distinction in
the survival curves between the groups of infants
infected with HIV-1 in comparison with those that were
uninfected, and no differences between those that were
co-infected with HIV-1 and HHV-8 and those infected
with HIV-1 alone. Although the HIV-1 and HHV-8
serologic status of all of the children in our cohort was
not established in this study but only maternal infection,
preliminary data from our study (data not shown)
suggest that whereas HIV-1 was vertically transmitted
from mothers to their infants, HHV-8 could be acquired
by these infants both by horizontal as well as perinatal
transmission (18, 39). For the infants of co-infected
mothers, HIV-1 infection probably accounted for the
greater part of the infant deaths in this study because the
relative frequency of HHV-8 infection by 12 months was
less than that of HIV-1 infection (18, 40).
The major limitation of our study was the annual loss
to follow-up rate of 10% to 15% at the 12th, 24th, and the
36th month visits. The difficulties encountered with
retention in this population highlight the need to
combine observational studies with interventional trials,
when possible, in such resource-limited areas. Despite
this occurrence, differential bias seemed to be minimized
as evidenced by the lack of any significant sociodemographic difference between the study participants and
those lost to follow-up. The significant differences in
HIV-1 and HHV-8 serostatus among those lost to followup at 48 months and those still in the cohort could be

Kaplan-Meier survival estimates, by group
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Fig. 1. Infant Kaplan-Meier survival
curves based on the mother's serologic
status.
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related to unverified deaths in these groups. It is possible
that the infant death rate may have been even higher
among the infants of co-infected mothers, and that the
HRs reported here may actually have been even higher if
we were able to completely track all participants.
The fact that we were unable to verify death through
death reports was another limitation of our study, as was
our inability to ascertain the HIV-l and HHV-8 infant
serostatus.
The result of this prospective, controlled observational
study, which, to our knowledge, is the largest of its kind
to date, suggests that there is appreciable infant mortality
associated with HIV-l infection in Zambia. However, we
also found that infants born to mothers dually infected
with both HIV-l and HHV-8 have comparable survival
with infants perinatally exposed to HIV-l alone, and that
exposure to HHV-8 does not increase risk of death in
comparison with unexposed infants.
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